Where it trades today
trading 97% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- DGX trades at 26.1x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- DGX carries a beta of 0.55, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- DGX is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in DGX.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for DGX come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for DGX. Last refresh: Sep 18, 2026, 10:56 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Quest Diagnostics does
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service…
Employees
46,000
Industry
Diagnostics & Research
Headquarters
Secaucus, United States
What analysts expect
DGX carries a buy consensus from 15 analysts, with an average price target of $246.73 versus $246.45 today (+0.1%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
DGX generated $11.56B in trailing revenue (10.2% year over year), with a 9.2% net margin, and $909.63M of free cash flow, against $5.78B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $11.04B | $3.67B | $1.56B | $992.00M | $8.87 | $1.36B |
| 2024 | $9.87B | $3.24B | $1.35B | $871.00M | $7.78 | $909.00M |
| 2023 | $9.25B | $3.05B | $1.26B | $854.00M | $7.59 | $864.00M |
| 2022 | $9.88B | $3.43B | $1.43B | $946.00M | $8.10 | $1.31B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
DGX beside the healthcare names it is usually measured against.
What the chart is saying
Quest Diagnostics trades at $246.45, 0.9% below its 52-week high. With a beta of 0.55, it shows less sensitivity to what the wider market does.
Questions people ask about it
Is DGX a good buy right now?
Quest Diagnostics trades at 26.1x earnings. This is near market average. Current risk level is Medium based on 21.2% volatility.
Does DGX pay dividends?
Yes, Quest Diagnostics offers a dividend yield of 1.39%. That is roughly $3.43 per share a year.
How volatile is DGX?
With 30-day annualized volatility of 21.2% and beta of 0.55, DGX is classified as Medium risk. The stock tends to be more stable than the market average.
What is the analyst price target for DGX?
The average analyst price target for Quest Diagnostics (DGX) is $246.73 based on 15 analyst estimates, about 0.1% above the current price of $246.45. The published range runs from $204.00 to $265.00.
How much revenue does DGX generate?
Quest Diagnostics reported $11.56B in trailing twelve-month revenue. Revenue growth is running at 10.2% year over year. Net margin sits at 9.2%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.